Abstract: Methods for treating or preventing allergic asthma and associated conditions in a subject are provided. Certain methods disclosed here comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-33 (IL-33) antagonist, such as an anti-IL-33 antibody. Other methods disclosed here comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4R (IL-4R) antagonist, such as an anti-IL-4R antibody. Still other methods disclosed here comprise administering to a subject in need thereof a first therapeutic composition comprising an interleukin-33 (IL-33) antagonist, such as an anti-IL-33 antibody, and a second therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody. Allergic asthma-associated signature genes are provided. Methods of altering (e.g.

Abstract: The present application relates to compositions and methods for treating allergy, e.g., peanut allergy, in patients. The methods involve administering glucopyranosyl lipid adjuvant (GLA) and peanut allergen(s) to the patient via a sublingual route.

Abstract: The present invention is directed to the substantially pure compound of formula (A), or pharmaceutically acceptable salt, or solvate of said compound; to a pharmaceutical composition comprising a pharmaceutically effective amount of the compound of formula (A), and a pharmaceutically acceptable carrier; and the use of a compound of formula (A) having activity as an inhibitor, preferably a selective inhibitor, of I?B (IKK), particularly IKK-2, and methods related thereto.